Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
 Securities Case - EconoTimes)
NEW YORK, March 15, 2016 -- Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that April 4, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Insys Therapeutics, Inc. (Nasdaq:INSY). Insys investors are encouraged to contact Scott + Scott at (866) 326-5057 or email [email protected] to discuss their legal rights.
About the Lawsuit
The complaint alleges that, throughout the Class Period, Defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Insys was engaged in the illegal and improper off-labeling marketing of Subsys; (2) certain Insys employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (3) as a result, Insys’ financial statements were materially false and misleading at all relevant times. After a series of news articles revealed that the Company had allegedly engaged in illegal and improper off-label marketing of Subsys, the Company’s shares fell dramatically in price, thereby injuring investors.
What you can do
If you purchased shares of Insys stock, you may have legal claims against the Company. If you want to discuss filing lead plaintiff papers, or have questions about your legal rights, please contact Geoffrey M. Johnson, Esq. or Joseph Halloran, Esq. by telephone at (866) 326-5057 or by email at [email protected] or [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott + Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio. Please visit www.scott-scott.com for more information about the firm.
CONTACT: Scott + Scott, Attorneys at Law, LLP Geoffrey M. Johnson, Esq. Joseph Halloran, Esq. (216) 229-6088, toll-free (866) 326-5057 [email protected] [email protected]
